# Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran

Study · id `cardio:ct-nct02331602` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02331602](<https://clinicaltrials.gov/study/NCT02331602>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02331602

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT02331602. Randomized; no masking; primary purpose treatment. Start 2013-07 (registry gives no type); primary completion 2015-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT02331602, source copy `cardio:ctgov-nct02331602-2015-08-06`, retrieved 2026-10-26)
- Start date: 2013-07 (registry gives no type) (ClinicalTrials.gov record NCT02331602, source copy `cardio:ctgov-nct02331602-2015-08-06`, retrieved 2026-10-26)
- Primary completion: 2015-10 (anticipated) (ClinicalTrials.gov record NCT02331602, source copy `cardio:ctgov-nct02331602-2015-08-06`, retrieved 2026-10-26)
- Completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT02331602, source copy `cardio:ctgov-nct02331602-2015-08-06`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02331602, source copy `cardio:ctgov-nct02331602-2015-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02331602-2015-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
- Acronym: RIVAL-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Dabigatran
- Lead sponsor: Yokohama City University Medical Center
- Lead sponsor class: OTHER
- Collaborator: Yokohama City University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Dabigatran (`cardio:dabigatran`)
- Registry lists this organization as the lead sponsor: Yokohama City University Medical Center (`cardio:org-yokohama-city-university-medical-center`)

## Provenance

Content hash: 6911c9384a4faaa45251ecac541f68bcec34fe708fa13eb87d9d09060dc96e27
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
